Skip to Main Content

In a rather unusual move, a Wall Street analyst has written an open letter to Gilead Sciences, imploring the drug maker’s executive team to pursue a “meaningful” acquisition before cash flow declines too precipitously.

The missive, which was written by Barclays Bank analyst Geoff Meacham, reflects ongoing investor frustration that the company has yet to pursue a deal to help compensate for declining sales of hepatitis C drugs and disappointing study results for newer medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!